Sign in
Taking peopleNo phase

Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis: A Real-World Cohort Study

Key facts

Who runs it
Second Affiliated Hospital of Soochow University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
990 people, planned
Started
1 Mar 2026
Expected to end
30 Jun 2029
Type of study
Observational, 2 groups
Treatments tested
  • Cilostazol-Based Dual Antiplatelet Therapy
  • Single Antiplatelet Therapy
Record updated
13 November 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age: 18-80 years old
  • Acute mild non-cardioembolic stroke
  • Ischemic stroke or transient ischemic attack (TIA) occurring 2 to 4 weeks prior to enrollment
  • NIHSS score ≤15 at enrollment and pre-stroke mRS score ≤2
  • Ischemic stroke or TIA attributable to the territory of the qualifying intracranial artery
  • Symptomatic 70%-99% intracranial atherosclerotic stenosis confirmed by DSA, CTA, or MRA

Who cannot take part

  • Current or previous severe heart failure
  • Severe bleeding event within the previous 6 months, including spontaneous intracranial hemorrhage, major gastrointestinal bleeding, or other bleeding requiring blood transfusion
  • High-risk cardioembolic source requiring or potentially requiring long-term anticoagulation, including persistent or paroxysmal atrial fibrillation, mechanical heart valve or severe valvular disease, intracardiac thrombus, recent myocardial infarction with significant wall-motion abnormality, or severe cardiomyopathy
  • Stroke or TIA caused by nonatherosclerotic disease, including moyamoya disease, vasculitis, arterial dissection, or other definite nonatherosclerotic causes
  • Known allergy or serious adverse reaction to cilostazol, aspirin, clopidogrel, ticagrelor, or other antiplatelet agents
  • Significant bleeding tendency or coagulation abnormality
  • Medical condition requiring long-term oral anticoagulation
  • Active malignancy or other serious illness with a life expectancy of less than 1 year
  • Severe cognitive impairment or psychiatric illness that would prevent adherence to study treatment or long-term follow-up

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to evaluate whether long-term dual antiplatelet therapy (DAPT) with cilostazol is associated with a lower risk of recurrent symptomatic ischemic stroke or all-cause mortality compared with single antiplatelet therapy (SAPT) in patients with symptomatic moderate-to-severe intracranial arterial stenosis following the completion of standard DAPT.

The 2 groups in the trial

  • Cilostazol-Based Dual Antiplatelet Therapy

    Participants who receive cilostazol 50 mg twice daily in combination with aspirin 100 mg once daily, clopidogrel 75 mg once daily, or ticagrelor 90 mg twice daily for 12 months according to routine clinical practice.

  • Single Antiplatelet Therapy

    Participants who receive single antiplatelet therapy with aspirin 100 mg once daily, clopidogrel 75 mg once daily, or ticagrelor 90 mg twice daily for 12 months according to routine clinical practice.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Secondary Preventive Effect of Long-term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Cerebral Infarction Patients With Symptomatic Moderate to Severe Intracranial Arterial Stenosis: A Real-World Cohort Study (SPDACSIS-COH)
Fit questions
Built from NCT07935408, who can take part
Record updated
13 November 2026